University of Kentucky

UKnowledge
Nursing Presentations

College of Nursing

4-2014

Tobacco Treatment for Individuals with Substance Abuse and
Psychiatric Disorders
Chizimuzo T.C. Okoli
University of Kentucky, ctokol1@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/nursing_present
Part of the Nursing Commons, and the Public Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Okoli, Chizimuzo T.C., "Tobacco Treatment for Individuals with Substance Abuse and Psychiatric
Disorders" (2014). Nursing Presentations. 3.
https://uknowledge.uky.edu/nursing_present/3

This Presentation is brought to you for free and open access by the College of Nursing at UKnowledge. It has been
accepted for inclusion in Nursing Presentations by an authorized administrator of UKnowledge. For more
information, please contact UKnowledge@lsv.uky.edu.

Tobacco Treatment for Individuals with
Substance Abuse and Psychiatric
Disorders

Chizimuzo Okoli, PhD, MPH, RN
Assistant Professor and Director,
Tobacco Treatment and Prevention Division, Tobacco Policy Research Program,
University of Kentucky College of Nursing

Overview
• Discuss smoking among persons with substance use
and mental illness
• Present smoking cessation outcomes from an
evidence-based program for persons with substance
use disorders and mental Illness

• Conclusion with current and future Projects

SMOKING AMONG PERSONS WITH
SUBSTANCE USE AND MENTAL
ILLNESS

Background and Significance

• “Nicotine-dependent
individuals with a
comorbid psychiatric
disorder made up 7.1%
of the population yet
consumed 34.2% of all
cigarettes smoked in the
United States”

Grant, B.F. , Hasin, D.S., Chou, S.P., Stinson, F.S.& Dawson, D.A. (2004). Nicotine dependence and psychiatric disorders in the United States: Results from a
national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry,61,1107-1115.

Past Month Cigarette Use among Adults Aged 18 or Older, by Any Mental Illness in
the Past Year and Gender, by Age Group: 2009 to 2011

Kalman, Morissette and George (2005), Am. J. Addict., 14: 106-123

Health effects of smoking among
persons with mental illness
Smokers with Mental illness :
• Die 10 years earlier
• Have more depression and
anxiety
• Have more substance use
problems
• Have more chest and heart
problems
• Are more likely to commit
suicide
• Have sexual problems

Nonsmokers with Mental illness :
• Have better health
• Live longer
• Need less medication
• Have less depression
• Save more money

Reasons for smoking among individuals with
substance use disorders and mental illness
• Genetic

• Bio-behavioral

• Psychosocial

Smoking and substance use: Genetic

•

Both common and specific addictive factors for alcohol, marijuana,
cocaine, and habitual smoking transmitted in families

•

This specificity suggested independent causative factors for the
development of each substance dependence

•

68% of the association between nicotine and alcohol dependence
explained by shared genetic effects.
Bierut LJ, Dinwiddie SH, Begleiter H, et al. Familial Transmission of Substance Dependence: Alcohol, Marijuana, Cocaine, and Habitual Smoking: A Report From the Collaborative
Study on the Genetics of Alcoholism. Archives of General Psychiatry 1998; 55:982-988
True WR, Xian H, Scherrer JF, et al. Common Genetic Vulnerability for Nicotine and Alcohol Dependence in Men. Archives of General Psychiatry 1999; 56:655-661

Smoking and mental illness: Genetic
(1,566 female twin pairs) average life
time daily cigarette consumption was
found to be associated with life time
prevalence of major depression,
suggesting that the relationship
between smoking and major
depression resulted solely from genes
which predispose to both conditions.
(8,169 male twins) shared
genetic factors further explain
the relationship between
major depression and nicotine
dependence.
Kendler KS, Neale MC, MacLean CJ, et al. Smoking and Major Depression: A Causal Analysis. Archives of General Psychiatry 1993; 50:36-43
Lyons M, Hitsman B, Xian H, et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine & Tobacco Research
2008; 10:97 - 108

Smoking and mental illness: Genetic

63% of the association between post traumatic stress disorder
and nicotine dependence co-morbidity explained by shared
genetic effects.

•

•

A group of candidate genes and individual genes found
among individuals with schizophrenia significantly linked to
smoking behaviors.
Koenen KC, Hitsman B, Lyons MJ, et al. A Twin Registry Study of the Relationship Between Posttraumatic Stress Disorder and Nicotine Dependence in Men. Archives of
General Psychiatry 2005; 62:1258-1265
Faraone et al. (2004). A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in Schizophrenia families

Smoking and substance use: Bio-behavioral
Marijuana use reduces cessation of tobacco smoking
in adults
Ford, Vu, Anthony. (2002) Drug and Alcohol Dependence; 67:243-248

Nicotine increases alcohol self-administration in
non-dependent male smokers.
Barrett,Tichauer, Leyton, et al. (2006). Drug and Alcohol Dependence; 81:197-204

Increases in methadone dose could increase nicotine
craving and cigarette consumption for individuals
with opioid-dependence
Story & Stark. (1991). Journal of psychoactive drugs, 23:203-215

Cigarette smoking primes the brain to cocaine use
Levine et al. (2011). Science translational medicine, 3, 107, 107-109

Smoking and mental illness: Bio-behavioral
Nicotine reduces sensorimotor gating deficits in
smokers with schizophrenia
Postma et al. (2006). Psychopharmacology, 184: 589–599

Brain levels of monoamine oxidase A (MAO-A) (an
enzyme associated with depression) were reduced
in smokers relative to nonsmokers; suggesting that
people with affective disorders may smoke to
reduce elevated MAO-A levels in the brain
Fowler, Volkow, Wang, et al. (1996). Proceedings of the National Academy of Sciences of the United States of America, 93:14065-14069

Smokers with a primary diagnosis of anxiety
disorder reported greater levels of general anxiety,
distress, and depression as compared to
nonsmokers.
McCabe, Chudzik, Antony, et al. (2004). Journal of Anxiety Disorders, 18:7-18

Substance use and Smoking: Psychosocial
• Tobacco use may foster the use of other substances; and
vice versa

• Drug treatment centers may provide an environment
that supports tobacco use or a factor for delayed
tobacco use cessation.

• Factors such as neighborhood disadvantage and early
exposure to substance use may present an ‘exposure
opportunity’ for subsequent substance use.
Glautier S, Clements K, White JAW, et al. Alcohol and the reward value of cigarette smoking. Behavioural Pharmacology 1996; 7:144-154
King AC, Epstein AM. Alcohol Dose-Dependent Increases in Smoking Urge in Light Smokers. Alcoholism: Clinical & Experimental Research 2005; 29:547-552
Friend KB, Pagano ME. Smoking initiation among nonsmokers during and following treatment for alcohol u se disorders. Journal of Substance Abuse Treatment 2004; 26:219-224
Bobo JK, Husten C. Sociocultural Influences on Smoking and Drinking. Alcohol Research & Health 2000; 24:225-232
Crum RM, Lillie-Blanton M, Anthony JC. Neighborhood environment and opportunity to use cocaine and other drugs in late childhood and early adolescence. Drug and Alcohol
Dependence 1996; 43:155-161
Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am. J. Epidemiol.
2002; 155:918-925

Smoking mental illness: Psychosocial
• History of tobacco use as a token economy-cigarettes used as a ‘reward’ for appropriate
behavior (i.e., smoking privileges)

• Smoking among clients and staff to encourage
‘socialization’

Kawachi I, Berkman L. Social ties and mental health. Journal of Urban Health 2001; 78:458-467
Lawn S. Cigarette smoking in psychiatric settings: occupational health, safety, welfare and legal concerns. Australian and New Zealand Journal of Psychiatry 2005; 39:886-891
Keizer I, Eytan A. Variations in Smoking during Hospitalization in Psychiatric In-Patient Units and Smoking Prevalence in Patients and Health-Care Staff. International Journal of Social
Psychiatry 2005; 51:317-328
Morisano D, Bacher I, Audrain-McGovern J, et al. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Canadian Journal Of Psychiatry. Revue
Canadienne De Psychiatrie 2009; 54:356-367

Arguments for Not Providing Tobacco Treatment….

“these patients don’t want to quit”
• However….80% of participants in a methadone maintenance
program and 75% of participants in an alcohol abuse
program endorsed a desire to quit
(Richter KP et al., 2001; Ellingstad TP et al, 1999)

• In a review of 9 studies of motivation to quit smoking among
individuals with psychiatric disorders at least 50% are
contemplating cessation
(Siru, Hulse & Tait, 2009).

“these patients will relapse (to other substances) if
they try to quit”
• Smoking cessation related to IMPROVED QUALITY OF LIFE

• Meta-analysis (n = 19 studies) of smoking cessation among
individuals in addiction treatment and recovery found that
smoking cessation efforts can ENHANCE rather than
compromise long-term sobriety

Bobo JK, McIlvain HE, Lando HA, et al. Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction 1998; 93:877887
McCarthy WJ, Zhou Y, Hser YI, et al. To smoke or not to smoke: Impact on disability, quality of life, and illicit drug use in baseline polydrug users. Journal of Addictive Diseases 2002; 21:35-54
Lemon SC, Friedmann PD, Stein MD. The impact of smoking cessation on drug abuse treatment outcome. Addictive Behaviors 2003; 28:1323-1331
Mc Carthy WJ, Collins C, Hser YI. Does cigarette smoking affect drug abuse treatment? Journal of Drug Issues 2002; 2:61-80
Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical
Psychology 2004; 72:1144-1156

“these patients are unable to quit”
• Meta-analysis (n = 19 studies) of smoking cessation among
individuals in addiction treatment and recovery found increased
cessation at end of 12 weeks treatment
(Prochaska JJ et al, 2004).

• Another recent study found end-of-treatment (between 8 to 26
weeks) smoking cessation rates of 40% among individuals with
SUD and/or PD who completed an intensive tailored smoking
cessation intervention that provided no-cost pharmacotherapy
combined with behavioural counseling
(Khara and Okoli, 2011)

Barriers to facilitating tobacco treatment
• Concerns that smoking cessation will increase
psychiatric symptoms or relapse among patients.
o Among individuals with depression, smoking cessation related to
increased depression symptomatology, which is one of the
symptoms of the nicotine withdrawal syndrome
o individuals with anxiety disorders and depression report more
severe withdrawal symptoms
o smoking is associated with improvements in prepulse inhibition
and sensory gating which may be affected by smoking cessation

• Smoke-free policy and mental health facilities
o a review of studies examining prohibitions of smoking in
psychiatric facilities suggests that prohibitions do not have longterm effects on behavioral unrest or noncompliance, but neither
do they appear to effect smoking cessation
Patten C, Martin J. Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Annals of Behavioral Medicine 1996; 18:190-200
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. American Journal of Psychiatry 1992;
149:464-469
Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Frontiers in Bioscience 2007; 12:4755-4772
Kumari V, Postma P. Nicotine use in schizophrenia: The self medication hypotheses. Neuroscience & Biobehavioral Reviews 2005; 29:1021-1034
el-Guebaly N, Cathcart J, Currie S, et al. Public health and therapeutic aspects of smoking bans in mental health and addiction settings. Psychiatr Serv 2002; 53:1617-1622
Ziedonis DMa, Williams JMb. Management of smoking in people with psychiatric disorders. Current Opinion in Psychiatry 2003; 16:305-315

Costs associated with smoking cessation treatment
• Even though less expensive than purchasing cigarettes,
the cost of pharmacotherapy and counseling presents
an important barrier to seeking treatment
• Such cost barriers to accessing treatment and the
potential cost-effectiveness of treatment have
prompted guidelines about reducing medication costs
(reduced cost or free of charge), inclusion of
medications as benefits on drug insurance plans, and
setting up systems for reimbursement for tobacco
cessation treatment for health care providers.

Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research 2004; 6:303310
Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health Nursing 2006; 15:272-278
Fiore M, Jaén C, Baker T, et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American Journal of Preventive
Medicine 2008; 35:158-176
Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. British Medical Journal 1999; 318:182-185

Smoking Cessation Outcomes of an evidencebased program for individuals with Substance
Use Disorders and Mental Illness

Program Overview
• 24-26 weeks (8 weeks structured, up to 18 weeks of support)
• Tailored pharmacotherapy for up to 26 weeks at no
cost
• Program is run with a team of nurses, counsellors,
respiratory therapists, Occupational therapists, and
a physician

TREATMENT PHILOSOPHY
Smoking cessation is a ‘process’ not an event. Hence the program has no
specific ‘quit date’. Also the program employs the concept of ‘titration-toeffect’ in which increasing doses of nicotine replacement therapy is
provided until the behavior of smoking ceases.

Criteria

Eligibility:
• 19 years or older
• Tobacco dependent
• Have a history of substance use disorder (SUD) and/or
psychiatric disorder (PD)
• Financially disadvantaged
Assessment:
• 1 hour evaluation of medical, psychiatric, substance
and tobacco use history
• Expired air CO is determined and a treatment plan is
developed in consultation with client

Phases of Treatment

Support Group

Tailored
Pharmacotherapy

Up to 24- 28
Weeks

Tailored
Tailored
Pharmacotherapy
Pharmacotherapy

8 -12 Weeks

Behavioral Counseling

Behavioural Counseling (Weeks 1-8)
• Phase 1: engagement in the process – weeks 1-2
• Phase 2: planning for change – weeks 3-4
• Phase 3: sustaining change – weeks 5-8

Combination Pharmacotherapy
Nicotine Replacement Therapy

Oral Medications

Patch

Gum

Zyban

Lozenge

Champix
Inhaler

Pender Clinic

DCHC

Rainier

Screen clipping taken: 12/03/2011, 11:18 AM

Raven Song

Three Bridges

Pacific Spirit
Centre for Concurrent Disorders

Sample for Evaluation
678
Intent-to-treat

155

523

Program non-completers

program completers

• Analysis is based on a retrospective chart review of participants in the TDC
program (between Sept 2007 and Dec, 2011) from 7 clinics, in Vancouver, Canada
• Smoking cessation: 7-day point-prevalence of abstinence at end of treatment
(i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels

Percent %

Substance Use Disorder & Psychiatric Disorder History
(N = 678)

7.2

100
80

14.0

60

33.9 Anxiety

40

13.3

20
0

21.7

Psychotic

65.3

26.1 None
10.3

11.9

9.4
Mood

3.5

0

20

40

24.3

60 54.480

100

Both
4.4
Substance use disorder
Psychiatric disorder
None

Sample Characteristics (N = 678, 57% male)
Mean

Stand. Dev.

Age of participant (years)

48.0

11.0

Age at smoking initiation (years)

15.1

5.8

Importance of quitting (scale of 0 ‘low’ to 10 ‘high’)

9.0

1.4

Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’)

7.2

2.4

Number of cigarettes smoked per day

20.4

10.3

Fagerstrom Test for Nicotine Dependence

6.0

2.0

20.9

14.2

(scale of 0 ‘low’ to 10 ‘high’)

CO level at baseline (ppm)

Program Completion (n = 523/678)
77.1%
100

Percent %

80
Yes

60

22.9%

40
20
0
Completed program?

No

Smoking Cessation* Outcomes at end-of-treatment
Quit
Not quit

100

67.3

59.7

80
60

32.7

40.3

40
20
0
Intent to treat (N=678)

Program completers (n = 523)

*Smoking cessation at end-of-treatment (i.e., anytime between 8 weeks to 26 weeks)
verified by expired CO levels

Smoking cessation by SUD and PD among
program completers (n = 523)*
100
Percent %

80

60
40

43.1

44.5

39.9

31.2

37.5

42.9

45.7

40.9

30.8

37.8

20
0

* No statistically significant differences between groups

Smoking cessation by Co-occurring Disorder history
(among program completers)*
100

Percent %

80
60

43.8

45.7

46.7

38.9

40
20
0
Neither
(n = 16)

Psychiatric
disorder only
(n = 35)

Substance use
disorder only
(n = 75)

Co-occurring
(n = 280)

* No statistically significant differences between groups

Smoking Cessation by length of stay in the program
(n = 678)*
100

Percent %

80
51.7

60

37.0
23.3

40

20
0

5.6

38.5

46.7

55.9
32.7

Multivariate predictorsa of program completion (n = 674)
Predictors

Odds Ratio

95%CI

Gender
Male (referent)
Female

1.0
1.78**

1.19-2.65

Age

1.03**

1.01-1.05

Hosmer-Lemeshow goodness-of-fit: χ2= 1.80 (DF=8), p=.986

a. Employing a two-step model building process in which variables associated with
smoking cessation (at alpha < 1.0) in the unadjusted analyses are included in a
second-step for adjusted analyses. Only variables which were significantly predictive of
smoking cessation in the final adjusted multivariate model are shown.
* = p <.05, ** = p <.001, *** = p <.001

Multivariate predictorsa of smoking cessation among
program completers at end of treatment (n = 494)
Predictors

Odds Ratio

95%CI

History of Psychiatric Disorder
None (referent)
Mood disorder
Anxiety disorder
Psychotic disorder

1.0
.90
.53*
.69

.57-1.42
.29-1.00
.31-1.57

FTND at baseline

.89*

.80-1.00

1.07***

1.04-1.10

Number of Visits to the TDC

Hosmer-Lemeshow goodness-of-fit: χ2= 3.45 (DF=8), p=.903
a.

Employing a two-step model building process in which variables associated with smoking cessation (at alpha < 1.0)
in the unadjusted analyses are included in a second-step for adjusted analyses. Only variables which were
significantly predictive of smoking cessation in the final adjusted multivariate model are shown.

* = p <.05, ** = p <.001, *** = p <.001

Conclusions
• With intensive tobacco dependence treatment provided
within Mental Health and Addictions services, individuals
with a history of substance use disorders and mental illness
are able to achieve smoking abstinence.
• Tobacco treatment should include best practices using
behavioural counseling combined with pharmacotherapy.
• Treatment durations beyond 12-weeks should be
considered to maximize effectiveness of programs

Current and Future Projects

• Current projects:
o Smoking Cessation Program among Individuals with Mental
Illness (PARTICIPATION STATION- a peer led mental health
support program in Lexington KY)
o Developing a tailored tobacco dependence treatment
intervention for individuals with Schizophrenia

• Future Projects:
o Examining the effect of different tobacco products on nicotine
dependence, symptoms severity, and smoking cessation
among individuals with mental illnesses.
o Examining barriers and opportunities to engagement and
provision of tobacco treatment within mental health treatment
facilities

Questions??

